A5042910272- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Tracheal and airway disorders
- Global Cancer Incidence and Screening
- Immunotherapy and Immune Responses
- Metabolism, Diabetes, and Cancer
- Cancer, Lipids, and Metabolism
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Gastrointestinal Tumor Research and Treatment
- Cardiovascular Disease and Adiposity
- Radiomics and Machine Learning in Medical Imaging
- Adipokines, Inflammation, and Metabolic Diseases
- Survey Methodology and Nonresponse
- Nutrition and Health in Aging
- Healthcare Policy and Management
- scientometrics and bibliometrics research
- Head and Neck Anomalies
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Pneumothorax, Barotrauma, Emphysema
- Colorectal Cancer Treatments and Studies
- IL-33, ST2, and ILC Pathways
- Cancer, Stress, Anesthesia, and Immune Response
Roswell Park Comprehensive Cancer Center
2023-2025
LabCorp (United States)
2024
University of Tennessee at Knoxville
2024
Thoracic Surgery Foundation
2024
Jawaharlal Institute of Post Graduate Medical Education and Research
2022
National Institute of Mental Health and Neurosciences
2022
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level (IPD) from the experimental arm...
Introduction Survival rates for early-stage non-small cell lung cancer (NSCLC) remain poor despite the decade-long established standard of surgical resection and systemic adjuvant therapy. Realizing this, researchers are exploring novel therapeutic targets deploying neoadjuvant therapies to predict improve clinical pathological outcomes in patients. Neoadjuvant therapy is also increasingly being used downstage disease allow with a curative intent. In this review, we aim summarize current...
Background: The prevalence of malignant central airway obstruction at diagnosis and its 5-year incidence are largely unknown, as basic epidemiological data pertaining to this serious condition. To address these limitations, we retrospectively collected from the cohort patients diagnosed with lung cancer our institution in 2015 followed 5 years forward, until 2020. Methods: We reviewed index PET/CT or CT scans time identify presence, subtype, severity well progression/development over next...
Background/Objectives: Non-small cell lung cancer (NSCLC) has seen a relative rise in incidence among females versus males recent years, although still have higher overall incidence. However, it is unclear whether this trend consistent across all populations. Therefore, we retrospectively examined relationship two large high-risk clinical cohorts. Methods: First, analyzed individuals with smoking history of over 40 pack-years the National Lung Screening Trial (NLST). Then, investigated...
•We found diverse immune checkpoint co-expression patterns in GEAC.•We showed that elevated PD-L1 expression was linked with increased of other checkpoints.•This supports as a biomarker advanced GEAC for combination immunotherapy.•CD8 T-cell noted different checkpoints, pointing toward potential combined immunotherapy. BackgroundAddition immunotherapy to standard chemotherapy marginally improved outcomes gastroesophageal adenocarcinoma (GEAC). Recently, dual has shown efficacy melanoma and...
Background: Malignant Central Airway Obstruction (MCAO) presents a significant challenge in lung cancer management, with notable morbidity and mortality implications. While bronchoscopy is the established diagnostic standard for confirming MCAO assessing obstruction subtype (intrinsic, extrinsic, mixed) severity, Computed Tomography (CT) serves as an initial screening tool. However, extent of agreement between CT findings remains unclear. Methods: To assess correlation CT, we conducted...
Pre-clinical cancer studies ascribe promising anticancer properties to metformin. Yet, clinical findings vary, casting uncertainty on its therapeutic value for non-small cell lung (NSCLC) patients. We hypothesized that metformin could benefit obese and overweight patients with NSCLC.
Background and objective There is a paucity of information regarding the concordance traditional metrics across publicly searchable databases about correlation between alternative for neurosurgical authors. In this study, we aimed to assess congruence reported Google Scholar (GS), Scopus (Sc), ResearchGate (RG). We also establish mathematical provided by ResearchGate. Methods Author names listed on papers published in Journal Neurosurgery (JNS) 2019 were collated. Traditional [number...
Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets their high expression in tumor cells immunogenic nature. We aimed explore the co-expression of CTAs GEAC. analyzed 63 GEAC patients initially validated our findings 329 from The Cancer Genome Atlas (TCGA) database. CTA was measured after RNA sequencing, while clinical information,...
Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets their high expression in tumor cells immunogenic nature. We aimed explore the co-expression of CTAs GEAC. analyzed 63 GEAC patients initially validated our findings 329 from The Cancer Genome Atlas (TCGA) database. CTA was measured after RNA sequencing, while clinical information,...
<h3>Background</h3> Potent anti-tumor and immunomodulatory properties have been ascribed to the diabetes drug metformin based on results of myriad preclinical studies.<sup>1–5</sup> However, clinical studies exploring potential benefits this as a cancer therapy inconsistent,<sup>6–12</sup> leaving metformin's therapeutic utility in treatment patients with non-small cell lung (NSCLC) other malignancies doubt. We hypothesized that safe inexpensive can benefit specific clinically significant...
<h3>Background</h3> Pembrolizumab monotherapy is established as an effective front-line treatment for advanced non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. However, real-world data on its long-term efficacy remains sparse. <h3>Methods</h3> This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and TPS Individual patient-level (IPD) from the experimental arm Keynote-024 trial were extracted (KN024 IPD...